Mode
Text Size
Log in / Sign up

Traditional Chinese Medicine and modern multi-organ networks offer integrated perspectives on the kidney-bone axisNew research explores ancient and modern ways to treat bone disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note the integration of traditional medicine and multi-organ networks in conceptualizing the kidney-bone axis.

This systematic review synthesizes the conceptual frameworks surrounding the kidney-bone axis, specifically focusing on conditions such as CKD-MBD, Renal Osteodystrophy, and Secondary Hyperparathyroidism. The authors identify shared holistic visceral-skeletal paradigms across Traditional Chinese Medicine, ancient Greek humoral theory, and the Ayurvedic Asthi Dhatu concept. These historical perspectives are contrasted with modern research, which has evolved through three stages: clinical-pathological observation, core molecular endocrine discoveries involving FGF23-Klotho, vitamin D, and OPG/RANKL/PTH, and current expansion into multi-organ networks involving gut microbiota, exosomes, and O-GlcNAc.

The review highlights significant gaps in the current evidence base, specifically noting insufficient high-level clinical evidence for current interventions. Challenges such as biomarker limitations and the difficulties of stratified therapy are also noted.

For clinical practice, the authors propose that integrated Chinese-Western strategies and multi-omics precision biomarkers may facilitate more personalized management of CKD-MBD. However, the lack of robust clinical data means these integrated approaches remain theoretical rather than established standard practices.

How this fits prior evidence

This review expands upon the link between gut microbiota dysbiosis and CKD-MBD, while also addressing the role of alpha-Klotho in bone health. It builds upon the established association between CKD-MBD medication titration and serum calcium, phosphorus, and parathyroid hormone levels by proposing a broader, multi-organ network approach to management.

Living with chronic kidney disease can lead to serious bone problems, a condition known as CKD-MBD. This makes it hard for patients to stay mobile and healthy. Scientists are now looking at how different medical traditions and modern science can combine to better manage these bone issues.

The review looked at how ancient systems, like Traditional Chinese Medicine and Ayurvedic medicine, shared similar ideas about the connection between the kidneys and the bones. They compared these old views to modern research. Today, doctors focus on specific molecules and hormones, like vitamin D and FGF23, to understand how the body manages bone health.

While the research shows a promising path toward personalized care, there are hurdles. Currently, there is a lack of high-level clinical evidence for many treatments. Scientists also face challenges with finding the right biomarkers to tailor therapy for every patient. The goal is to create a more precise way to manage bone health for those with kidney disease.

What this means for you:
Combining ancient medical concepts with modern molecular science may help create better ways to treat bone issues in kidney patients.

Common questions

What is CKD-MBD?

CKD-MBD is a condition where chronic kidney disease leads to problems with the bones and minerals. It is also known as renal osteodystrophy or secondary hyperparathyroidism. These terms describe how the body struggles to maintain healthy bones when the kidneys are not working correctly.

How does modern medicine treat these bone issues?

Modern research focuses on the kidney-bone axis. This involves studying specific molecules like vitamin D, FGF23, and Klotho. Scientists are also looking at how the gut and other organs affect bone health to find better ways to treat patients.

Is there enough evidence for new treatments?

Currently, there is a lack of high-level clinical evidence for many current interventions. While the research suggests that combining different medical strategies could help, more high-quality evidence is needed to confirm the best way to treat these patients.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
The kidney-bone axis constitutes a conserved bidirectional endocrine network that orchestrates skeletal remodeling and systemic mineral homeostasis. Its dysregulation underlies chronic kidney disease-mineral and bone disorder (CKD-MBD), renal osteodystrophy, secondary hyperparathyroidism, and associated vascular calcification, markedly elevating fracture and cardiovascular mortality risks. This review offers a unique cross-cultural and chronological synthesis of the kidney-bone relationship, bridging ancient medical insights with modern molecular endocrinology. Horizontally, we systematically compare the “kidney governing bones” doctrine in Traditional Chinese Medicine (TCM), ancient Greek humoral theory, and Ayurvedic Asthi Dhatu concept, revealing their shared holistic visceral-skeletal paradigm as the primitive prototype of contemporary multi-organ crosstalk, while highlighting distinct interpretive and therapeutic frameworks. Vertically, modern research is delineated into three developmental stages: (1) clinical-pathological observation of renal osteodystrophy and vitamin D-PTH disturbances (19th–early 20th century); (2) core molecular endocrine discoveries centered on the FGF23-Klotho, vitamin D, and OPG/RANKL/PTH signaling axes; and (3) expansion to novel multi-organ networks involving gut microbiota-derived uremic toxins, exosomes, and O-GlcNAc modification. We further summarize the multi-target mechanisms of kidney-tonifying TCM formulas (e.g., Zuogui Pill, Gushudan) and Western interventions, critically analyze translational bottlenecks—including biomarker limitations, stratified therapy challenges, and insufficient high-level clinical evidence—and propose integrated Chinese-Western strategies, multi-omics precision biomarkers, and cross-cultural theoretical fusion to advance personalized management of CKD-MBD and related metabolic bone diseases.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.